Treats myasthenia gravis. ANDA 212702, held by Amneal. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 212702 (Pyridostigmine Bromide), held by Amneal, was first approved by FDA on Jan 10, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS Pyridostigmine bromide oral solution is useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 10, 2020 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pyridostigmine Bromide60MG/5ML · syrup;oral | Pyridostigmine Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters